05th week of 2016 patent applcation highlights part 11 |
Patent application number | Title | Published |
20160030547 | SWINE INFLUENZA VIRUSES AND CONSTRUCTS AND USES THEREOF - Disclosed are compositions and methods comprising vectors and a reverse genetics competent unit comprising one or more recombinant influenza viruses. Recombinant influenza viruses comprising swine RNA polymerase I promoter are disclosed. Constructs comprising swine RNA polymerase I promoter nucleic acid sequences are also provided. Methods of inducing protecting immunity with the recombinant influenza viruses are disclosed. In certain embodiments, the reverse genetics competent unit comprises pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector for influenza virus in swine. | 2016-02-04 |
20160030548 | Influenza Nucleic Acid Molecules And Vaccines Made Therefrom - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotpyes using the vaccines that are provided. | 2016-02-04 |
20160030549 | RECOMBINANT RSV WITH SILENT MUTATIONS, VACCINES, AND METHODS RELATED THERETO - In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated. | 2016-02-04 |
20160030550 | COMPOSITIONS, VECTORS, KITS, AND METHODS FOR IMMUNIZING AGAINST AVIAN INFECTIOUS BRONCHITIS VIRUS - Disclosed are compositions, vectors, kits, and methods for inducing an immune response against avian infectious bronchitis virus (IBV). In particular, the compositions, vectors, kits, and methods may be utilized to immunize poultry against disease associated with IBV infection or to protect poultry from IBV infection altogether. | 2016-02-04 |
20160030551 | SINGLE HIGH DOSE OF MVA INDUCES A PROTECTIVE IMMUNE RESPONSE IN NEONATES AND INFANTS - The invention relates to compositions and methods for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age. The invention encompasses administering a single high dose of an MVA to a human neonate or infant of less than 6 months of age, wherein the administration induces protective T- and B-cell responses against a poxvirus in the human neonate or infant. | 2016-02-04 |
20160030552 | IMMUNE MODULATION - The present invention relates to a poxvirus vector comprising a nucleic acid sequence encoding a fusion protein comprising: (i) a peanut allergen selected from list consisting of at least two peanut allergens from ara h 1, ara h 2, ara h 3, ara h 4, ara h 5, ara h 6. ara h 7, ara h 8, ara h 9, ara h I O and ara h I I or a derivative or part thereof having at least 70% sequence identity thereto, and (ii) a profeasome degradation tag to enhance intracellular degradation of the fusion protein. Methods of desensitizing or inducing tolerance to a peanut allergen and/or suppressing an allergic response to a peanut allergen are also disclosed. | 2016-02-04 |
20160030553 | ALLERGEN PREPARATION - Allergen preparation comprising an allergen in an oil-in-water emulsion. | 2016-02-04 |
20160030554 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY - Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen. | 2016-02-04 |
20160030555 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+ REGULATORY T CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells. | 2016-02-04 |
20160030556 | Bovine Virus Vaccines That Are Liquid Stable - The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, and a sugar alcohol. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines. | 2016-02-04 |
20160030557 | Vaccines Having an Antigen and Interleukin-23 As An Adjuvant - Disclosed herein is a vaccine comprising an antigen and IL-23. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof. | 2016-02-04 |
20160030558 | ENHANCEMENT OF VACCINES - Provided is a method for enhancing the efficacy of cancer vaccines, such as tumor vaccines. The method involves administering to an individual who is in need of therapy for a tumor an anti-cancer agent and an agent that causes depletion of myeloid cells and/or inhibits recruitment of myeloid cells to the tumor. The effect of the anti-cancer agent on the tumor is greater relative to the effect of the anti-cancer agent in the absence of the anti-myeloid cell agent. Also provided is a method for identifying candidates for the therapy. This approach involves determining if an individual has a tumor characterized by undesirable myeloid cell proliferation and/or tumor infiltration and/or myeloid cell recruitment to the tumor, and if such determination is made, designating the individual as a candidate for the therapy. In one embodiment, the identification of the individual as such a candidate is followed by the therapeutic approach. | 2016-02-04 |
20160030559 | BIOMARKER HSP90 FOR PREDICTING EFFECT OF A C-MET INHIBITOR - A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90. | 2016-02-04 |
20160030560 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS - The present disclosure is directed to adeno-associated viral vector monoclonal antibody constructs and compositions thereof, methods of improving locomotor function after spinal cord injury, methods of treating neurodegenerative diseases. | 2016-02-04 |
20160030561 | Methods of Treating Pancreatic Cancer - Novel methods of treating pancreatic cancer are provided. In one embodiment, the method comprises determining NOTCH mRNA expression levels in pancreatic cancer cells. In another embodiment, the method further comprises administering to a subject in need thereof a therapeutically effective dose of a NOTCH antagonist. | 2016-02-04 |
20160030562 | METHODS TO ENHANCE CANCER TREATMENT - Herein are provided methods for reducing or eliminating cancer in a patient in need of cancer treatment, by providing cholesterol deprivation therapy (CDT) in conjunction with antibodies directed against cholesterol-deprived tumor cells. Further provided are methods of enhancing the efficacy of other cancer treatments, by administering CDT and antibodies directed against cholesterol-deprived tumor cells, in combination with additional anti-cancer therapies. | 2016-02-04 |
20160030563 | CONCENTRATED HUMAN IMMUNOGLOBULIN COMPOSITION - A liquid pharmaceutical composition containing human immunoglobulin G, preferably at 230 g/l or higher. The composition, suitable for subcutaneous or intramuscular administration, can be used to treat various diseases, e.g., an antibody production defect and Kawasaki disease. | 2016-02-04 |
20160030564 | BIOPHOTONIC MATERIALS AND USES THEREOF - The present disclosure provides topical biophotonic materials and methods useful in phototherapy. In particular, the topical biophotonic materials of the present disclosure include a cohesive matrix, and at least chromophore which can absorb and emit light from within the topical biphotonic material, wherein the topical biophotonic material is elastic. The topical biophotonic materials and the methods of the present disclosure are useful for promoting wound healing and skin rejuvenation, as well as treating acne and various other skin disorders. | 2016-02-04 |
20160030565 | USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF - The invention provides the use of a photosensitiser which is a derivative (e.g. an ester) of 5-aminolevulinic acid (5-ALA), or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises:
| 2016-02-04 |
20160030566 | TREATMENT OF MULTIPLE SCLEROSIS - A composition for treating neurodegeneration, including an antibiotic, an antifungal agent, and a lipophilic potentiating agent in synergistically effective amounts. A method of treating neurodegeneration, by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration, and treating neurodegeneration. A method of reducing and/or eliminating symptoms of neurodegeneration, by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration, and reducing and/or eliminating the individual's symptoms of neurodegeneration. A method of reducing and/or eliminating lesions from neurodegeneration. A method of recovering mobility of an individual suffering from neurodegeneration. | 2016-02-04 |
20160030567 | Topical Homeopathic Remedies for Generalized Dermatitis - The present invention relates to a topical homeopathic remedy for skin conditions generally known as dermatitis. The present invention further relates to a composition forming said topical homeopathic remedy, a process for creating such composition and a method of using same. The present invention may comprise a combination of at least one of the following compounds: | 2016-02-04 |
20160030568 | COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER - This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium. The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects. | 2016-02-04 |
20160030569 | LOW-GLYCERIN FORMULATIONS FOR HIV TREATMENT AND PREVENTION - The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-pur: in-9-yl)-1-methyl-ethoxymethy]-phosphonic acid (tenofivir, PMPA), or a physiologically functional derivative thereof, wherein the formulations contain a low level of glycerin. Human immunodeficiency vims (HIV) infection and related diseases are a major public health problem worldwide. One approach to the problem of HIV/AIDS is to reduce the risk of transmission of HIV and thus reduce the number of individuals who become newly infected. | 2016-02-04 |
20160030570 | FORMULATIONS OF BIOLOGICS FOR INTRAVESICAL INSTILLATION - Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed. | 2016-02-04 |
20160030571 | THERAPEUTIC AGENT FOR FIBROID LUNG - Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent. | 2016-02-04 |
20160030572 | LIQUID FORMULATIONS - Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow. | 2016-02-04 |
20160030573 | STABLE PHARMACEUTICAL COMPOSITIONS OF 5,10-METHYLENETETRAHYDROFOLATE - This invention relates to stable pharmaceutical compositions of 5,10-methylene-(6R)-, -(6S)-, or -(6R,S)-tetrahydrofolate (MTHF), by adjusting a basic pH and the simultaneous use of citrate. Stabilisation is effected even in the absence of a reducing agent. The present invention is particularly suitable for producing lyophlisation solutions and lyophilisates or dry powders and dry mixtures, since the stable MTHF solutions can be used in high concentrations for filling corresponding vessels such as vials, ampoules, etc. The lyophilisates have a surprisingly long shelf life and are surprisingly stable. They can be reconstituted without problems by adding wateror aqueous solutions, and the final clear injection solutions again exhibit excellent stability properties. Moreover, the present invention even makes it possible to prepare difficulty soluble calcium 15 or acidic salts of MTHF in high concentrations and as physiologically compatible isotonic solutions. | 2016-02-04 |
20160030574 | PHARMACEUTICAL COMPOSITION 271 - The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions. | 2016-02-04 |
20160030575 | TAXOID - PURIFICATION PRINCIPLE FOR LIQUID EXCIPIENTS - The invention relates to taxoid compositions having improved stability. | 2016-02-04 |
20160030576 | EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE - The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol. | 2016-02-04 |
20160030577 | LIPOPEPTIDE COMPOSITIONS AND RELATED METHODS - The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose. | 2016-02-04 |
20160030578 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2016-02-04 |
20160030579 | Stabilization of Essential Oils Within a Hydrocolloid Adhesive - Various adhesive compositions are described which comprise one or more essential oils. The adhesive compositions may optionally comprise one or more active agents such as pharmaceutical agents. Also described are related methods of improving the stability of essential oil(s) in adhesive compositions by incorporating polyvinylpyrrolidone. Also described are related methods of using the compositions and articles incorporating such compositions. | 2016-02-04 |
20160030580 | TOPICAL DAPSONE AND DAPSONE/ADAPLENE COMPOSITIONS AND METHODS FOR USE THEREOF - Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder. | 2016-02-04 |
20160030581 | BIODEGRADABLE DRUG DELIVERY COMPOSITIONS - A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed. | 2016-02-04 |
20160030582 | ITRACONAZOLE COMPOSITIONS AND DOSAGE FORMS, AND METHODS OF USING THE SAME - The disclosure relates to, among other things, pharmaceutical compositions, such as solid oral dosage forms, comprising itraconazole, methods of making the compositions, and methods of using the same for treating disorders including, but not limited to, fungal infections. | 2016-02-04 |
20160030583 | PHARMACEUTICAL COMPOSITIONS WITH SYNCHRONIZED SOLUBILIZER RELEASE - Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer. | 2016-02-04 |
20160030584 | METHOD FOR PRESERVING AND STABILISING PROTEINS, WHICH CAN BE USED FOR INDUSTRIAL DEVELOPMENT OF FORMULATIONS OF SANITARY, PHARMACEUTICAL AND COSMETIC PRODUCTS - A method for preserving and stabilising proteins is disclosed which can be used for the industrial development of formulations of sanitary, pharmaceutical and cosmetic products, particularly cell growth factors and/or proteins such as epidermal growth factor (EGF) and fibroblast growth factor (bFGF). The method includes a dispersion phase, under normal pressure and temperature conditions, in which the proteins are incorporated into an anhydrous medium formed by oily components that have hydrophilic residues and that guarantee interactions with the proteins, while maintaining the native conformation of the proteins, such components being grape seed oil, a base of different components and butylhydroxytoluene. | 2016-02-04 |
20160030585 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES - The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: | 2016-02-04 |
20160030586 | Immunogenic Composition in Emulsion Form - The present invention relates to an immunogenic composition comprising a continuous aqueous phase and a dispersed phase as droplets and comprising:
| 2016-02-04 |
20160030587 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY - Conjugates of an anti-TNF antibody and one or more nonpeptidic water soluble polymers are provided. Typically, the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient. | 2016-02-04 |
20160030588 | IMMUNE-POTENTIATING DRUG NANOCARRIERS AND METHODS OF PRODUCTION AND USE THEREOF - Described herein are nanoparticle-based compositions, kits, methods and platforms for delivering drugs to professional APCs (PAPCs) in vivo resulting in a robust and specific immune response to a pathogen, e.g., | 2016-02-04 |
20160030589 | Methods of Producing Cancer Compounds - Provided is a method for making the compound of Formula 1: | 2016-02-04 |
20160030590 | VECTORS FOR DELIVERY OF AGENTS ACROSS BIOLOGICAL MEMBRANES - The disclosure provides for peptide-based bolaamphiphile vectors that are capable of encapsulating a variety of agents, including peptides, proteins, nucleic acids, and drugs. The disclosure further provides for delivering these agents across biological membranes using the peptide-based bolaamphiphile vectors. | 2016-02-04 |
20160030591 | BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES - The present disclosure relates to linker compounds that are useful in covalently linking biologically active molecules with Ligands. The disclosed compounds also relate to biologically active molecules and Ligand conjugates, wherein the biologically active molecule is linked to the Ligand through a linker. The disclosure further provides compositions comprising biologically active molecule-ligand conjugates, methods of modifying abnormal cell growth and methods of treatment using the conjugates or the compositions. | 2016-02-04 |
20160030592 | Polyoxazoline Antibody Drug Conjugates - In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer ADCs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (DAR) of the antibody significantly beyond the currently available technology. This may be of particular importance when antibodies to low density antigens are used as target antibodies. The described polymer-ADCs have improved pharmacokinetics and solubility relative to traditional ADCs. The linker between agent and the polymer can be tailored to provide release of toxin at the desired site and under the desired conditions within the tumor. An additional feature of the polymer-ADCs of the current disclosure is that a purification moiety can be attached to the polymer backbone to provide ease of purification of the polymer-ADCs. | 2016-02-04 |
20160030594 | ANTIBODY DRUG CONJUGATES - The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer. | 2016-02-04 |
20160030595 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS - Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding | 2016-02-04 |
20160030596 | GAS-FILLED STABILIZED PARTICLES AND METHODS OF USE - Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described. | 2016-02-04 |
20160030597 | S100B MINI-PROMOTERS - Isolated polynucleotides comprising a S100B mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, gene therapy, etc. | 2016-02-04 |
20160030598 | Reaction-Based Fluorescent Probes for Detecting Zinc - Disclosed are compounds and methods useful in the detection of e.g., Zn | 2016-02-04 |
20160030599 | PARTICLES COMPRISING LUMINESCENT LANTHANIDE COMPLEXES - The present invention relates to particles, useful for drug release detection, comprising:
| 2016-02-04 |
20160030600 | TARGETED DELIVERY OF NANOPARTICLES TO EPICARDIAL DERIVED CELLS (EPDC) - This invention relates to nanoparticles for use in the in vivo diagnostics of epicardial derived cells (EPDCs) to nano particles for use in the treatment of cardiac injury. The invention further relates to a method for analyzing EPDCs, to a method for labeling EPDCs, and to a method for transferring a therapeutic agent into an EPDC. | 2016-02-04 |
20160030601 | RADIOPAQUE CONTRAST AGENT - A radiopaque composition is provided that includes an inorganic opacifying agent distributed through an aqueous gelatinous substance in an aqueous solvent. A process for making a radiodense vascular fill composition includes adding a gelatinous substance to an aqueous solution. An inorganic opacifying agent suspension is formed in a saline solution or water. The inorganic opacifying agent and gelatin are mixed with water or saline. A process of imaging a vascular system of a subject includes placing a subject under anesthesia or sedation and exsanguinating the subject. An isotonic fluid is then flushed through the vascular system and the radiopaque composition is infused into the subject circulatory system at a temperature of 40 degrees Celsius or greater. After waiting a given time interval for the radiopaque composition to cool and form a solid gel, an imaging scan is performed on the subject. | 2016-02-04 |
20160030602 | IMAGEABLE EMBOLIC MICROSPHERE - This invention concerns imageable, radiopaque embolic beads, which are particularly useful for monitoring embolization procedures. The beads comprise iodine containing compounds which are covalently incorporated into the polymer network of a preformed hydrogel bead. The beads are prepared by activating pre-formed hydrogel beads towards nucleophilic attack and then covalently attaching iodinated compounds into the polymer network. The radiopaque beads may be loaded with chemotherapeutic agents and used in methods of embolizing hyperplastic tissue or solid tumors. | 2016-02-04 |
20160030603 | DETECTION OF ACUTE RENAL ALLOGRAFT REJECTION - The invention provides a method of detecting acute renal allograft rejection in a subject as well as a method of stratifying a subject received a renal allograft and undergoing immunosuppressive therapy for alteration of the therapy. These methods comprise administering to the subject a probe capable of specifically binding to T lymphocytes, the probe being detectable by ultrasound. An allotransplanted kidney of the subject is exposed to ultrasound. The level of T lymphocytes in the kidney is detected. An elevated level of T lymphocytes in the kidney indicates an increased risk of renal allograft rejection and/or that the subject is in need of an alteration of the immunosuppressive therapy. | 2016-02-04 |
20160030604 | COMPOSITIONS AND METHODS FOR ASSESSING NEUROMUSCULAR FUNCTION - The invention provides compositions and methods for evaluating neuromuscular function in a subject, e.g., a subject at risk for or suffering from a neuromuscular disorder. | 2016-02-04 |
20160030605 | 18F-LABELED PSMA-TARGETED PET IMAGING AGENTS - Compounds of Marlush formula (I) described in the claims are useful in diagnostic methods for detecting and/or identifying cells presenting PSMA. Disclosed are also methods for preparing the compounds. Representative compounds according to the application are: | 2016-02-04 |
20160030606 | RADIO-LABELLED ANTIBODY FRAGMENTS FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER - The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (V | 2016-02-04 |
20160030607 | HEAT FLUX CONTROL FOR LIQUID NITROGEN SPRAYS - A freezer apparatus for treating a product with cryogen includes a source of cryogen liquid and a source of cryogen gas; a first conduit for delivering a first amount of the cryogen liquid; a second conduit in fluid communication with the first conduit for delivering a second amount of the cryogen gas into the cryogen fluid for being mixed therewith to provide a cryogen mixture having a ratio selected of cryogen gas:cryogen liquid; and a delivery apparatus in fluid communication with the first conduit downstream of the second conduit, the delivery apparatus including at least one outlet through which the cryogen mixture passes for contacting a surface of the product. A related method is also provided. | 2016-02-04 |
20160030608 | AUTOCLAVE FOR STERILISATION - Provided is an autoclave for sterilisation including a sterilisation chamber, a tank of water, connection means configured to connect the tank to the sterilisation chamber in a fluidic through connection, heating means configured to heat and to pressurise the water and to supply the sterilisation chamber to perform sterilisation cycles, in which the tank includes a filter, the tank is in addition divided into a high potential portion and a low potential portion, the portions being in reciprocal fluidic through connection through the filter, the filter comprising a plurality of filtering layers including distribution layers configured to slow down and improve the distribution of the water along the entire area of the layers and active layers configured to perform purification functions of the water. | 2016-02-04 |
20160030609 | DISINFECTING LIGHT FIXTURE - Disclosed herein is a light fixture. The light fixture includes at least one first light source that emits at a peak wavelength in a range of approximately 380 nm to approximately 420 nm and at least one second light source that emits at a different peak wavelength, wherein a combined light output of the at least one first light source and the at least one second light source emits a colored light that is perceived as white light. The white light is defined by having a color rendering index (CRI) value of more than approximately 50. The at least one second light source that emits at a different peak wavelength consists of an xy coordinate on a International Commission on Illumination (CIE) 1931 xy color space diagram above a black body curve within a bounded area defined by a first line of approximately y=2.23989x−0.382773 and a second line of approximately y=1.1551x−0.195082. The combined light output has a proportion of spectral energy measured in the approximately 380 nm to approximately 420 nm range of greater than approximately 20%. | 2016-02-04 |
20160030610 | DISINFECTING LIGHT FIXTURE - Disclosed herein is a light fixture. The light fixture includes at least one first light source that emits at a peak wavelength in a range of approximately 380 nm to approximately 420 nm and at least one second light source that emits at a different peak wavelength, wherein a combined light output of the at least one first light source and the at least one second light source emits a colored light that is perceived as white light. The white light is defined by having a color rendering index (CRI) value of more than approximately 50. The at least one second light source that emits at a different peak wavelength consists of an xy coordinate on a International Commission on Illumination (CIE) 1931 xy color space diagram above a black body curve within a bounded area defined by a first line of approximately y=2.23989x−0.382773 and a second line of approximately y=1.1551x−0.195082. The combined light output has a proportion of spectral energy measured in the approximately 380 nm to approximately 420 nm range of greater than approximately 20%. | 2016-02-04 |
20160030611 | PROCESSING UNIT AND METHOD FOR SEPARATING HYDROCARBONS FROM FEEDSTOCK MATERIAL - A processing unit and method for separating hydrocarbons from feedstock material. The processing unit includes at least one rotating conveyor in communication with a material inlet and a material outlet; a vacuum pump providing a vacuum atmosphere within the rotating conveyor; at least one material transfer device positioned at the material inlet and at least one material transfer device positioned at the material outlet, each material transfer device configured to allow transfer of feedstock material into or out of the rotating conveyor whilst maintaining the vacuum atmosphere within the rotating conveyor; and an electrostatic generator connected to the rotating conveyor providing a static charge to the vacuum atmosphere within the rotating conveyor. The method includes rotating the feedstock material in at least one rotating conveyor in communication with a material inlet and a material outlet; providing a vacuum atmosphere within the rotating conveyor; providing a static charge to the vacuum atmosphere within the rotating conveyor; transferring the feedstock material into and out of the rotating conveyor through at least one material transfer device positioned at the material inlet and at least one material transfer device positioned at the material outlet, each material transfer device allowing transfer of feedstock material into or out of the rotating conveyor whilst maintaining the vacuum atmosphere within the rotating conveyor. | 2016-02-04 |
20160030612 | MOBILE PHONE CHARGER WITH STERILIZATION ULTRAVIOLET LED - A mobile phone charger with a sterilization UV LED may include: a charger case having a space formed therein and including a mobile phone stand formed at the front surface thereof; and one or more first UV LEDs installed at one side of the space of the charger case. | 2016-02-04 |
20160030613 | Apparatus for the Disinfection of Medical Instruments - Devices, methods and systems of disinfecting medical instruments, more particularly blood glucose meters. A disinfection cradle including a flat base for positioning the cradle on a surface, the cradle having a receptacle configured to receive the diagnostic apparatus, and a UV source positioned in the receptacle that is configured to administer a disinfection cycle to the diagnostic apparatus by directing UV light outward at the diagnostic apparatus received in the receptacle, the UV light being able to act as a disinfecting agent to the disinfection cradle and diagnostic apparatus. | 2016-02-04 |
20160030614 | ANTISEPTIC COMPOSITIONS, METHODS AND SYSTEMS - Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections. | 2016-02-04 |
20160030615 | DEVICE FOR EVAPORATING A LIQUID AND RELATED METHOD | 2016-02-04 |
20160030616 | INCUBATOR HOOD, INCUBATOR HAVING THE SAME, HYDROPHILIC SHEET FOR INCUBATORS, AND HYDROPHILIC ANTIBACTERIAL FILM FOR INCUBATORS - The present invention provides an incubator hood having a hydrophilized portion on at least a part of its inner surface, the hydrophilized portion containing a hydrophilic polymer and an antibacterial agent, and a surface of the hydrophilized portion having a water contact angle of up to 30°, and also provides an incubator having the incubator hood as well as a hydrophilic sheet and a hydrophilic antibacterial film for use in forming the hydrophilized portion on the incubator hood. Thus the present invention provides an incubator hood, an incubator, a hydrophilic sheet and a hydrophilic antibacterial film that have excellent antifogging properties and antibacterial properties and can suppress the growth of bacteria. | 2016-02-04 |
20160030617 | Sterilization Container with Movable and Nestable Lid - A sterilization container includes a floor. A first sidewall is connected to a first side of the floor and a second sidewall is connected to a second side of the floor wherein each of the first and second sidewalls has an elongated blind cavity formed along a length thereof. A first hinge is positioned partially within the blind cavity of the first sidewall, and a second hinge is positioned partially within the blind cavity of the second sidewall, wherein each of the first and second hinges are movable along a length of the first and second blind cavities, respectively. A lid is connected between the first and second hinges and is positionable between a first position substantially parallel with the floor on a third side of the floor, and a second position substantially parallel with the floor on a fourth side of the floor. | 2016-02-04 |
20160030618 | PREVENTATIVE SOLUTION AND METHOD OF USE - A preventative solution includes an aqueous base, 1 wt % to 6 wt % titanium dioxide having an average particle size of not greater than 100 nm, 0.5 wt % to 20 wt % alcohol having 2 to 4 carbons, and 3 wt % to 15 wt % of a binding agent. The preventative solution can be dispersed using a fogger, for example, sequentially with an odor neutralizing solution or a disinfectant solution. | 2016-02-04 |
20160030619 | Fruit and Clove Pomander Kit - A fruit and clove pomander kit for efficiently creating a pomander using fruit and cloves. The fruit and clove pomander kit includes a carving and piercing tool having a piercing end adapted to create pierced holes within a fruit and a carving end opposite of the piercing end. The kit further includes a plurality of dried cloves, a rubber band, a writing instrument and at least one hanger hook. The hanger hook is comprised of a helical portion, an engaging portion extending upwardly from the helical portion and an end portion extending downwardly from the helical portion opposite of the engaging portion. The end user uses the kit to create a pomander with a piece of fruit. | 2016-02-04 |
20160030620 | AIR FRESHENER DISPENSERS, CARTRIDGES THEREFOR, SYSTEMS, AND METHODS - Automated air freshener dispensers and cartridges therefor are provided herein. Air freshener dispensers include a housing having a cavity for receiving a cartridge containing an air freshening substance for release, a fan that induces an airflow through the housing and directs the airflow to an area outside of the air freshener dispenser, such that released air freshening substance is entrained in the airflow, a motor for driving the fan, at least one sensor, and a controller that receives a signal from the at least one sensor and directs operation of the fan in response thereto. | 2016-02-04 |
20160030621 | SYSTEM AND METHOD OF CONTROLLING OPERATION OF A LIQUID DIFFUSION APPLIANCE - A method and system of controlling operation of a diffusion appliance to treat the atmosphere within an enclosed space. The appliance may be programmed to operate according to a control scheme specifying a flow rate of liquid to a diffusion means and a periodic operation of the diffusion means. Control schemes may be associated with different volumes of spaces to be treated by the appliance. Anti-fatigue schemes may provide variation of the flow rate or periodic operation of the appliance. Initiation controls schemes may be used to start treatment of the space before the appliance is programmed to operate according to one of the control schemes. | 2016-02-04 |
20160030622 | Multiple Plasma Driven Catalyst (PDC) Reactors - The present invention relates to an air purification system with plasma driven catalyst technology. The system comprises a plurality of plasma driven catalyst reactors in a parallel setup. Zigzag electrodes comprising zigzag structures are used to facilitate plasma generation. The system of the present invention provides the advantages with ease of fabrication and scaling-up, and improvement of air purification performance. | 2016-02-04 |
20160030623 | COHERENT BLOOD COAGULATION STRUCTURE OF WATER-INSOLUBLE CHITOSAN AND WATER-DISPERSIBLE STARCH COATING - An absorbent layer for moderating blood flow from a wound has a non-woven fabric layer of water-insoluble chitosan fibers having a coating of water-absorbent starch on at least one face of the fabric layer. The coating of water-absorbent starch penetrates into the fabric layer from a first surface over the chitosan fibers to a depth of at least 25% of the fabric layer of chitosan fibers. The chitosan fibers have average diameters of from 5 to 30 micrometers. The average weight of starch/chitosan may decrease from the first surface from which the starch has penetrated into the fabric to the depth of at least 50% of the fabric layer. The starch may be modified to include hydrophilic groups into or onto molecular chains of the starch. | 2016-02-04 |
20160030624 | METHODS AND COMPOSITIONS FOR WOUND HEALING - The present invention relates to methods and compositions for wound healing. In particular, the present invention relates to promoting and enhancing wound healing by utilizing cross-linker covalent modification molecules to attach and deliver wound active agents to a wound. In addition, the present invention provides methods and compositions utilizing oppositely charged polyelectrolytes to form a polyelectrolyte layer on a wound surface. The invention further relates to incorporating wound active agents into a polyelectrolyte layer for delivery to a wound. | 2016-02-04 |
20160030625 | POROUS POLYMER COMPOSITES - Porous polymer composites and methods of preparing porous polymer composites are provided herein. In some embodiments, a method for preparing porous polymer composites may include mixing a first polymer with a solvent and a particulate filler to form a first polymer composition, wherein the amount of particulate filler in the first polymer composition is below a mechanical percolation threshold; and removing the solvent from the first polymer composition to concentrate the first polymer and particulate filler into a second polymer composition having a porous structure, wherein the particulate filler concentration in the second polymer composition is increased above the mechanical percolation threshold during solvent removal. | 2016-02-04 |
20160030626 | Rapid Setting High Strength Calcium Phosphate Cements Comprising Cyclodextrins - Rapid setting high strength calcium phosphate cements and methods of using the same are provided. Aspects of the cements include fine and coarse calcium phosphate particulate reactants and a cyclodextrin which, upon combination with a setting fluid, produce a flowable composition that rapidly sets into a high strength product. The flowable compositions find use in a variety of different applications, including the repair of hard tissue defects, e.g., bone defects such as fractures. | 2016-02-04 |
20160030627 | KIT FOR ADHERING BIOLOGICAL HARD TISSUES - A kit for bonding to biological hard tissues, containing a phosphorylated polysaccharide, a polyvalent metal salt other than phosphates, and a solvent. The adhesive composition for biological hard tissues provided by the kit for bonding to biological hard tissues is suitably used in for medical uses, such as cement for bones or dental cement. In addition, since the adhesive composition has excellent bio-absorbability, it is useful as fusion materials for artificial joint prosthesis, fusion materials for spine fracture, fusion materials for extremity fracture, filling materials for bone tumors in the region of orthopedics, filling materials and restorative materials at dental caries-defective sites, luting materials for prosthetic restorative materials such as inlay and crown, pulp-capping and lining materials, implant surface treatment materials, periodontal disease therapeutic materials, hyperesthesia preventive materials, dental pulp capping materials, substrates for DDS, substrates for systems engineering, and tissue bonding materials in the dental region. | 2016-02-04 |
20160030628 | TREATMENT FOR BILE LEAKAGE - Materials and methods for treating bile leakage are disclosed. A peptide comprising between about 7 amino acids to about 32 amino acids may be introduced to a target site. The peptide may undergo self-assembly upon adjustment of a pH level of the solution to a physiological pH level. | 2016-02-04 |
20160030629 | PEPTIDE-ALBUMIN HYDROGEL PROPERTIES AND ITS APPLICATIONS - Peptide-albumin hydrogels having a self-assembling, | 2016-02-04 |
20160030630 | ANTI-FUNGUS METHODS AND KIT FOR TREATMENT OF FUNGAL NAIL INFECTIONS - The present invention relates generally to methods and related kit to maximize the effectiveness of anti-fungus medicines including Vicks Vapor Rub and to mitigate the spread of infection to other toes or fingers and to other people. The kit consists of part of disposable nitrile glove or the like, anti-fungus medicine such as topical drug, and a tape. Barrier-inverting method and rolling-up method have been disclosed on how to apply the kit to the infected areas. | 2016-02-04 |
20160030631 | Injectable Biodegradable Bone Matrix for Multiple Myeloma Lesion Augmentation and Osteoporosis - Bone filler compositions, methods of making and using the same, and methods of treating osteoporosis and cancer-induced bone defects, are described. | 2016-02-04 |
20160030632 | Bonding of Titanium Coating to Cast CoCr - Described is a medical implant having a CoCr cast body and a commercially pure (CP) Ti coating. The CP Ti coating is diffusion bonded to the CoCr body and is 5-3000 μm thick. Also described is a process for producing the medical implant that includes preparing the cast CoCr body for coating, applying a coating using a cold spray process, and diffusion bonding the coating to the body using hot isostatic pressing. | 2016-02-04 |
20160030633 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. | 2016-02-04 |
20160030634 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion. | 2016-02-04 |
20160030635 | IMPROVED METHOD OF MAKING EXTRACELLULAR MATRIX COMPOSITIONS - Provided herein are methods of producing extracellular matrix (ECM) that are superior to previously-described methods. Extracellular matrix (ECM) comprises protein that forms many structures in the body including tendons, ligaments, and sheets that support skin and internal organs. There remains a need in the art for ECM compositions that have improved cell attachment characteristics and methods of making such ECM compositions. | 2016-02-04 |
20160030636 | Method for Decellularization of Tissue Grafts - The subject invention pertains to materials and methods for processing tissue to produce a natural, acellular replacement tissue that is immunocompatible with a recipient. According to the subject invention, harvested tissue is subjected to wash solutions wherein only amphoteric detergent(s) are used (e.g., anionic detergents are excluded). Following extraction by amphoteric detergent(s), the tissue is washed with a buffer system to facilitate the clearance of cellular components and detergent. In one embodiment, the subject invention pertains to a replacement tissue that is a nerve graft that supports axonal regeneration, guides axons toward the distal nerve end and/or is immunologically tolerated. Preferably, the nerve graft retains essential extracellular matrix scaffolding as well as biological components that promote nerve regeneration through the nerve graft. | 2016-02-04 |
20160030637 | USE OF MICROPARTICLES AND ENDOTHELIAL CELLS WITH DECELLULARIZED ORGANS AND TISSUES - The invention provides a method for maintaining capillary lumen diameter, reducing a decrease in capillary vessel lumen diameter or expanding capillary vessel lumen diameter in a re-endothelialized decellularized organ or tissue graft with an intact extracellular matrix vascular network. The method is based on administration of endothelial cells and microparticles to the decellularized ECM. | 2016-02-04 |
20160030638 | USE OF PERFUSION DECELLULARIZED LIVER FOR ISLET CELL RECELLULARIZATION - The invention provides a method for preparing a perfusion based islet cell containing extracellular matrix of liver, an islet cell recellularized extracellular matrix, and methods of using the recellularized matrix. | 2016-02-04 |
20160030639 | Allografts Combined with Tissue Derived Stem Cells For Bone Healing - There is disclosed a method of combining mesenchymal stem cells (MSCs) with a bone substrate. In an embodiment, the method includes obtaining tissue having MSCs together with unwanted cells. The tissue is digested to form a cell suspension having MSCs and unwanted cells. The cell suspension is added to the substrate. The substrate is cultured to allow the MSCs to adhere. The substrate is rinsed to remove unwanted cells. In various embodiments, the tissue is adipose tissue, muscle tissue, or bone marrow tissue. In an embodiment, there is disclosed an allograft product including a combination of MSCs with a bone substrate in which the combination is manufactured by culturing MSCs disposed on the substrate for a period of time to allow the MSCs to adhere to the substrate, and then rinsing the substrate to remove unwanted cells from the substrate. Other embodiments are also disclosed. | 2016-02-04 |
20160030640 | CARBON NANOTUBES AND GRAPHENE PATCHES AND IMPLANTS FOR BIOLOGICAL TISSUE - The present invention relates to a novel composition comprising carbon nanotubes and/or graphene and a supporting material that can be used as an implant, patch or construct for the treatment, repair or replacement of biological tissue, including musculoskeletal tissue, fascia tissue, dura tissue, epidermal tissue, blood vessels and arteries, and organs. The present invention is also a method of manufacturing the novel composition, and a method of using the novel composition to treat, repair or replace biological tissue. | 2016-02-04 |
20160030641 | MIXED-PHASE BIOMATERIALS - A method of preparing a mixed-phase thermoplastic biomaterial comprises contacting and reacting a diol and a graft pre-polymer comprising a diol and at least one covalently bonded unsaturated monomer with an organic diisocyanate compound. The reaction is conducted within an aprotic solvent and for a period of time and at a temperature sufficient to produce the mixed-phase thermoplastic biomaterial. The diol may be selected from the group consisting of siloxane diols, polyether diols, polyester diols and polycarbonate diols while the at least one covalently bonded unsaturated monomer may be selected from the group consisting of a fluorinated monomer, a siloxane monomer, an aliphatic ester of methacrylic acid, a cyclic ester of methacrylic acid, a charged monomer, a sulfonium salt, a vinyl monomer with phenol or benzoic acid, N-vinyl pyrrolidone, an aminoglucoside, and a therapeutic agent. The mixed-phase thermoplastic biomaterial may further include an anti-microbial, a therapeutic agent or both. | 2016-02-04 |
20160030642 | STENT WITH PREFERENTIAL COATING - This invention relates to stents, a type of implantable medical device, with an antiproliferative coating and a prohealing luminal coating and methods of fabricating stents with an antiproliferative coating and a prohealing luminal coating. | 2016-02-04 |
20160030643 | DRUG COATED STENTS - Provided herein is a coated coronary stent including a stent framework, heparin molecules attached to the stent framework and a rapamycin-polymer coating wherein at least part of rapamycin is a crystalline form. In one embodiment, the rapamycin-polymer coating comprises one or more resorbable polymers. Methods for preparing stents are also disclosed. | 2016-02-04 |
20160030644 | WELDED STENT WITH RADIOPAQUE MATERIAL LOCALIZED AT THE WELDS AND METHODS - A stent that includes a stent body and one or more weld joints, wherein the weld joints include a radiopaque material, and a method of making a stent that includes using a radiopaque filler material in a welding process. | 2016-02-04 |
20160030645 | SYSTEMS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF REDUCED PRESSURE EMPLOYING RECONFIGURABLE LUMENS - Systems, method, and devices are disclosed that involve reconfiguring lumens or unblocking lumens relative to a blockage to maintain flow of reduced pressure to a subcutaneous tissue site. In one instance, a multi-lumen applicator includes an applicator body having a distal end and a proximal end and formed with a plurality of apertures for receiving fluid from the tissue site and for delivering reduced pressure, a first lumen fluidly coupled to the plurality of apertures, a first activation member having at least a closed position and a open position, and a second lumen fluidly coupled to the plurality of apertures but for the first activation member being in closed position. The configuration is such that when the first activation member is moved to the open position, the second lumen is fluidly coupled to the plurality of apertures. Other systems, methods, and devices are disclosed. | 2016-02-04 |
20160030646 | COMPRESSIBLE WOUND FILLERS AND SYSTEMS AND METHODS OF USE IN TREATING WOUNDS WITH NEGATIVE PRESSURE - Apparatuses and methods disclosed herein relate to various embodiments of wound fillers that, in some cases, preferentially collapse in one direction as compared to another direction. Such apparatuses and methods may aid in the closure of wounds and may further be used in combination with pressure sensors and controllers to provide for controlled collapse of the wound fillers. | 2016-02-04 |
20160030647 | SYSTEM AND METHOD TO INCREASE THE OVERALL DIAMETER OF VEINS - A system and method for increasing the speed of blood and wall shear stress (WSS) in a peripheral vein for a sufficient period of time to result in a persistent increase in the overall diameter and lumen diameter of the vein is provided. The method includes pumping blood at a desired rate and pulsatility. The pumping is monitored and adjusted, as necessary, to maintain the desired blood speed, WSS and pulsatility in the peripheral vein in order to optimize the rate and extent of dilation of the peripheral vein. | 2016-02-04 |